OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.
Miniaturized high-throughput screening is applicable to bispecific antibody development.
October 11, 2021
MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, signed an agreement with Cellecta to license its genome-editing tool.
October 08, 2021
Pfizer may pay up to $630 million for access to Voyager’s novel AAV capsids in transgene research.
October 06, 2021
New excipients for protein-based drug products reduce viscosity while maintaining protein stability.
The collaboration between Sunovion, Sumitomo Dainippon, and Otsuka will focus on four compounds designed to treat neuropsychiatric health conditions.
October 05, 2021
Merck and Ridgeback Biotherapeutics' oral antiviral medication reduced the risk of hospitalization or death from COVID-19 by 50% relative to placebo in a Phase III clinical study.
October 04, 2021
Takeda will use Selecta Bioscience’s ImmTOR platform to develop gene therapies for lysosomal storage disorders.
October 02, 2021
The complexity of newer biotherapeutic molecules calls for alternative drug delivery strategies.
Speed-to-market, capacity, technology development, and increased investment top the list.
The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.
October 01, 2021
Change of roster does not change the goal line. We are all patients first.